BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 01, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Champix varenicline regulatory update

EMA's CHMP concluded the slightly increased risk of cardiovascular events reported from a meta-analysis of Champix varenicline from Pfizer does not outweigh the benefits of the smoking cessation drug. CHMP said it could not draw a robust conclusions from the study for which it identified a number of limitations, including the low number of events observed, the types of events counted, the higher drop...

Read the full 297 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >